IRI — Integrated Research Income Statement
0.000.00%
Last trade - 00:00
- AU$71.59m
- AU$52.61m
- AU$69.83m
- 85
- 74
- 88
- 94
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 101 | 111 | 78.5 | 62.9 | 69.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 71.9 | 80 | 70 | 67.1 | 101 |
Operating Profit | 28.9 | 30.9 | 8.47 | -4.27 | -31.5 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 29.6 | 31.5 | 9.31 | -2.44 | -29.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21.9 | 24.1 | 7.93 | 1.54 | -29.2 |
Net Income Before Extraordinary Items | |||||
Net Income | 21.9 | 24.1 | 7.93 | 1.54 | -29.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 21.9 | 24.1 | 7.93 | 1.54 | -29.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.127 | 0.139 | 0.043 | 0.004 | -0.05 |
Dividends per Share |